Item 8.01 Other Events

On October 12, 2020, RegeneRx Biopharmaceuticals, Inc. (the "Company") issued a press release announcing that it has verbally agreed to a short-term financing transaction with one of its major stockholders, and members of its board of directors and management. The funding will provide working capital through the first quarter of 2021 and while we await the completion of our phase 3 dry eye clinical trial (ARISE-3) expected later this year. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description

  99.1          Press Release dated October 12, 2020

© Edgar Online, source Glimpses